-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Protalix BioTherapeutics, Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q2 2023 to Q2 2024.
- Protalix BioTherapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was -$69K, a 97.8% increase year-over-year.
- Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$3.09M.
- Protalix BioTherapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was $0.000.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)